Literature DB >> 15156316

Herpes simplex infection in urothelial carcinoma.

Naomi Kaku1, Kenji Kashima, Tsutomu Daa, Iwao Nakayama, Shigeo Yokoyama.   

Abstract

Herpes simplex virus (HSV), a member of the Herpesviridae family, is a very common pathogen that can infect any site in the body. Urothelial carcinoma (UC) is a common malignancy of the urinary tract. The possibility of HSV infection in cases of UC has attracted little attention. In this study, we investigated the possible presence of HSV in UC and non-neoplastic urothelium. We examined the incidence of HSV infection in 100 samples of UC from 78 patients and 50 samples of non-neoplastic urothelium from 50 autopsy cases using immunohistochemical staining and amplification of DNA using polymerase chain reaction (PCR). Infection by HSV was detected in 39 of the 100 samples of UC (35 of 78 patients) using immunohistochemical staining and/or PCR analysis, in marked contrast with 1 of 50 samples of non-neoplastic urothelium. There was no significant relationship between infection by HSV and anatomical site, growth pattern or depth of invasion of UC, but the frequency of HSV infection was significantly higher in females than in males. Our findings indicate that UCs become infected with HSV much more easily than non-neoplastic urothelium.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15156316     DOI: 10.1007/s00428-004-1019-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  12 in total

1.  Multiple infections in cases of cervical cancer from a high-incidence area in tropical Africa.

Authors:  R Schmauz; P Okong; E M de Villiers; R Dennin; L Brade; S K Lwanga; R Owor
Journal:  Int J Cancer       Date:  1989-05-15       Impact factor: 7.396

2.  Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors.

Authors:  M N Kitaeva; L Grogan; J P Williams; E Dimond; K Nakahara; P Hausner; J W DeNobile; P W Soballe; I R Kirsch
Journal:  Cancer Res       Date:  1997-10-15       Impact factor: 12.701

3.  Further studies on an immunoenzymatic assay for herpes simplex virus tumor-associated antigen.

Authors:  G Tarro; G Flaminio; S Maturo; C Esposito; R Cocchiara
Journal:  Clin Immunol Immunopathol       Date:  1982-10

Review 4.  Herpes simplex virus infections.

Authors:  R J Whitley; B Roizman
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

5.  HSV-2-induced tumorigenicity in HPV16-immortalized human genital keratinocytes.

Authors:  J A DiPaolo; C D Woodworth; N C Popescu; D L Koval; J V Lopez; J Doniger
Journal:  Virology       Date:  1990-08       Impact factor: 3.616

6.  Longitudinal follow-up of antibody response to selected antigens of human papillomaviruses and herpesviruses in patients with invasive cervical carcinoma.

Authors:  E Hamsíková; V Ludvíková; R Tachezy; J Kovarík; L Brousková; V Vonka
Journal:  Int J Cancer       Date:  2000-05-01       Impact factor: 7.396

7.  Herpes simplex virus type 2: a possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer.

Authors:  A Hildesheim; V Mann; L A Brinton; M Szklo; W C Reeves; W E Rawls
Journal:  Int J Cancer       Date:  1991-09-30       Impact factor: 7.396

8.  Prevalence of papillomavirus, Epstein-Barr virus, cytomegalovirus, and herpes simplex virus type 2 in urinary bladder cancer.

Authors:  P Gazzaniga; R Vercillo; A Gradilone; I Silvestri; O Gandini; M Napolitano; L Giuliani; A Fioravanti; M Gallucci; A M Aglianò
Journal:  J Med Virol       Date:  1998-08       Impact factor: 2.327

9.  Immunofluorescent evidence of prior herpes simplex virus type-2 infection in prostate carcinoma.

Authors:  M Haid; N Sharon
Journal:  Urology       Date:  1984-12       Impact factor: 2.649

10.  Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark)--a second look.

Authors:  S K Kjaer; E M de Villiers; H Cağlayan; E Svare; B J Haugaard; G Engholm; R B Christensen; K A Møller; P Poll; H Jensen
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.